Table 1 Baseline demographics, clinical and laboratory features of ISR among CAD patients with syphilis undergoing PCI
Variables | Total n(%) | ISR n(%) | Non-ISR n(%) | p |
|---|---|---|---|---|
Patients number | 114 (100) | 18 (100) | 96 (100) | - |
Demographic and clinical data | ||||
 Age ≥ 50 years | 93 (81.6) | 16 (88.9) | 77 (80.2) | 0.589 |
 Gender-Male | 91 (79.8) | 13 (72.2) | 78 (81.3) | 0.578 |
 Smoking history | 77 (67.5) | 13 (72.2) | 64 (66.7) | 0.644 |
 Alcoholic drinking | 50 (43.9) | 12 (67.7) | 38 (39.6) | 0.034 |
 Cardiovascular syphilis | 6 (5.26) | 1 (5.56) | 5 (5.21) | 1.000 |
 Hypertension | 65 (57.0) | 9 (50.0) | 56 (58.3) | 0.512 |
 Diabetes | 42 (36.8) | 8 (44.4) | 34 (35.4) | 0.466 |
 Chronic kidney disease | 2 (1.75) | 0 (0.00) | 2 (2.08) | 1.000 |
Coronary angiography | ||||
 Number of target vessels |  |  |  |  |
 One | 30 (26.3) | 2 (11.1) | 28 (29.2) | 0.063 |
 Two | 26 (22.8) | 3 (16.7) | 23 (24.0) | 0.711 |
 Multivessel disease | 58 (50.9) | 13 (72.2) | 45 (46.9) | 0.048 |
Target vessels | ||||
 LM | 18 (15.8) | 2 (11.1) | 16 (16.7) | 0.810 |
 LAD | 103 (90.4) | 18 (100.0) | 85 (88.5) | 0.282 |
 LCX | 68 (59.6) | 13 (72.2) | 55 (57.3) | 0.236 |
 RCA | 77 (67.5) | 16 (88.9) | 61 (63.5) | 0.035 |
 Implanted stent numbers > 3 | 21 (18.4) | 8 (44.4) | 13 (13.5) | 0.006 |
 Average stent length ≥ 35 mm | 13 (11.4) | 4 (22.2) | 9 (9.38) | 0.242 |
 Average stent diameter ≤ 3 mm | 93 (81.6) | 17 (94.4) | 76 (79.2) | 0.229 |
Laboratory data | ||||
 Dyslipidemia | 76 (66.7) | 14 (77.8) | 62 (64.6) | 0.276 |
 TG > 2.3 mmol/L | 19 (16.7) | 4 (22.2) | 15 (15.6) | 0.730 |
 TC > 6.2 mmol/L | 2 (1.75) | 0 (0.0) | 2 (1.75) | 1.000 |
 HDL < 1 mmol/L | 64 (56.1) | 12 (66.7) | 52 (54.2) | 0.327 |
 LDL > 3.12 mmol/L | 10 (8.77) | 1 (5.56) | 9 (9.38) | 0.943 |
 HCY > 15umol/L | 47 (41.2) | 11 (61.1) | 36 (37.5) | 0.062 |
 TPPA | 114 (100) | 18 (100) | 96 (100) | - |
 Titres of TRUST > 1:16 | 14 (12.3) | 6 (33.3) | 8 (8.33) | 0.010 |
Clinical treatment | ||||
 Statins | 74 (64.9) | 14 (77.8) | 60 (62.5) | 0.213 |
 β-Blocker | 46 (40.3) | 12 (66.7) | 34 (35.4) | 0.013 |
 Glucose-lowering agents* | 26 (22.8) | 1 (5.56) | 25 (26.0) | 0.111 |
 Effective DAPT | 78 (68.4) | 13 (72.2) | 65 (67.7) | 0.705 |
 Successful antisyphilitic treatment | 49 (43.0) | 1 (5.56) | 48 (50.0) | 0.001 |